Synopsis: Venus Remedies Limited, a Pharma Stock, reports 40.51% QoQ revenue growth and a 473.50% YoY net profit surge in Q2 FY26 results.
This Micro-cap Pharma Stock, engaged in the research, development, manufacturing, and marketing of innovative and affordable pharmaceutical products, including antibiotics, anti-infectives, and specialty medicines, jumped 18.31 percent after the company reported September quarterly results with a 473.50 percent YoY increase in net profit.
With a market capitalization of Rs. 718.07 crores, the share of Venus Remedies Limited has reached an intraday high of Rs. 555 per equity share, rising nearly 18.31 percent from its previous day’s close price of Rs. 469.10. Since then, the stock has retreated and is currently trading at Rs. 537.20 per equity share.
Q2 FY26 Result Walkthrough:
Coming into the quarterly results of Venus Remedies Limited, the company’s consolidated revenue from operations increased by 13.32 percent YOY, from Rs. 170.10 crore in Q2 FY25 to Rs. 192.75 crore in Q2 FY26, and grew by 40.51 percent QoQ from Rs. 137.18 crore in Q1 FY26.
In Q2 FY26, Venus Remedies Limited’s consolidated net profit increased by 473.50 percent YOY, reaching Rs. 20.13 crore compared to Rs. 3.51 crore during the same period last year. As compared to Q1 FY26, the net profit has increased by 109.69 percent, from Rs. 9.60 crore.
The basic earnings per share increased by 472.62 percent and stood at Rs. 15.06 as against Rs. 2.63 recorded in the same quarter in the previous year, FY2025.
Venus Remedies Limited’s revenue and net profit have grown at a CAGR of 7.68 percent and 29.1 percent, respectively, over the last two years.
In terms of return ratios, the company’s ROCE and ROE stand at 11.1 percent and 7.16 percent, respectively. Venus Remedies Limited has an earnings per share (EPS) of Rs. 52.6, and its debt-to-equity ratio is 0.02x.
Company Overview:
Venus Remedies Limited was established in 1989 and is an Indian pharmaceutical company focused on research-driven innovation. It specializes in developing, manufacturing, and marketing a wide range of pharmaceutical products that serve healthcare needs globally. The company is committed to providing affordable and quality medicines.
Venus Remedies is primarily engaged in producing antibiotics, anti-infectives, and specialty medicines, emphasizing injectable formulations. Its manufacturing units follow stringent quality standards and are approved by multiple international regulatory authorities, supporting its reach across global markets.
The company offers an extensive product portfolio covering therapeutic segments such as anti-infectives, analgesics, cardiovascular, and dermatology products. It also invests in research and development to introduce new and improved medicines, reinforcing its position as a trusted pharmaceutical firm.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
